« Return to News | Awards & Advancement

BMS appoints Francis Cuss as executive vice president, CSO

Monday, April 8, 2013 03:00 PM

Bristol-Myers Squibb, a global biopharmaceutical company, has appointed Francis Cuss, MB, BChir, FRCP, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., retires.

Cuss has a strong medical background, and broad experience in both research and development. Prior to joining BMS, he spent 14 years at Schering-Plough and three years at Glaxo, holding positions of increasing responsibility in discovery, clinical research and medical affairs in both the U.S. and Europe.

Cuss joined BMS in 2003 as senior vice president of drug discovery, adding responsibility for discovery medicine and clinical pharmacology in May 2006. Cuss and his team successfully integrated Adnexus, Medarex and ZymoGenetics into the research organization, and have driven innovation in the research operating model, processes and governance. He became a member of the company's senior management team in 2010.

Elliot Sigal has served as the company's chief scientific officer since 2004 and on the company's board of directors since 2011. He will retire from both positions effective June 30, 2013. Sigal and Cuss will continue to work together until that time.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.